Amgen Denosumab Osteoporosis Submission To Await Three-Year Data
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm had previously planned to submit denosumab for postmenopausal osteoporosis with two-year data.
You may also be interested in...
Amgen’s Four-Year Denosumab Data Shows Bone Density Benefit
Wyeth also presents the first Phase III fracture data on its potential competitor Viviant.
Amgen’s Four-Year Denosumab Data Shows Bone Density Benefit
Wyeth also presents the first Phase III fracture data on its potential competitor Viviant.
Amgen Partners With Daiichi-Sankyo For Denosumab In Japan
Amgen and Daiichi-Sankyo have entered a collaboration and license agreement for development and commercialization of Amgen's investigational bone loss therapy denosumab in Japan, the companies announced July 11